Amin Solouki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amin Solouki has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Hamed Soleimani Samarkhazan
Student Research Committee, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications Ahmed Hussein
The Islamic University
1 shared publication- Ali Rahmati
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Athena Behforouz
Shahid Beheshti University of Medical Sciences
1 shared publication Ehsan Lotfi
Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication- Fatemeh Sotudeh Chafi
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 17 September 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 13-45
Placental-Derived Products for Corneal Regeneration: Applications of Amniotic Membrane, Cord Blood Serum, and Stem Cells: A Review
- 17 September 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 13-45
Placental-Derived Products for Corneal Regeneration: Applications of Amniotic Membrane, Cord Blood Serum, and Stem Cells: A Review
- Open Access
- 29 April 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
“Unraveling the Clot-Miscarriage Nexus: Mechanisms, Management, and Future Directions in Thrombosis-Related Recurrent Pregnancy Loss”
Recurrent spontaneous abortion (RSA) is a multifactorial condition influenced by genetic, hormonal, immunological, and anatomical factors. Thrombophilia, characterized by a heightened propensity for blood clotting, is a significant contributor to RSA. This review examines the mechanisms connecting thrombosis and RSA, focusing on hypercoagulable states, placental thrombosis, inflammation, and endothelial dysfunction. Genetic and acquired thrombophilic factors, such as factor V Leiden mutation, prothrombin gene mutation, protein C and S deficiencies, antithrombin III deficiency, antiphospholipid syndrome, and hyperhomocysteinemia, are discussed in detail. The diagnosis of thrombophilia in RSA entails a comprehensive clinical evaluation, including the assessment of physical examination, medical history and laboratory investigations, although there is still debate over the need for universal screening. Therapeutic strategies, including anticoagulant and antiplatelet therapies, as well as lifestyle modifications, are tailored to individual risk factors and disease severity. Although anticoagulant therapy demonstrates potential in lowering the risk of miscarriage, additional research is necessary to refine treatment protocols and assess long-term outcomes. This review highlights the need for a nuanced approach to managing thrombophilia-associated RSA, balancing diagnostic precision with therapeutic efficacy to improve reproductive outcomes.
- 29 April 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Open Access“Unraveling the Clot-Miscarriage Nexus: Mechanisms, Management, and Future Directions in Thrombosis-Related Recurrent Pregnancy Loss”
Recurrent spontaneous abortion (RSA) is a multifactorial condition influenced by genetic, hormonal, immunological, and anatomical factors. Thrombophilia, characterized by a heightened propensity for blood clotting, is a significant contributor to RSA. This review examines the mechanisms connecting thrombosis and RSA, focusing on hypercoagulable states, placental thrombosis, inflammation, and endothelial dysfunction. Genetic and acquired thrombophilic factors, such as factor V Leiden mutation, prothrombin gene mutation, protein C and S deficiencies, antithrombin III deficiency, antiphospholipid syndrome, and hyperhomocysteinemia, are discussed in detail. The diagnosis of thrombophilia in RSA entails a comprehensive clinical evaluation, including the assessment of physical examination, medical history and laboratory investigations, although there is still debate over the need for universal screening. Therapeutic strategies, including anticoagulant and antiplatelet therapies, as well as lifestyle modifications, are tailored to individual risk factors and disease severity. Although anticoagulant therapy demonstrates potential in lowering the risk of miscarriage, additional research is necessary to refine treatment protocols and assess long-term outcomes. This review highlights the need for a nuanced approach to managing thrombophilia-associated RSA, balancing diagnostic precision with therapeutic efficacy to improve reproductive outcomes.
- Open Access
- 28 April 2025
- Published by Springer Nature in Thrombosis Journal
- Vol. 23 (1) , 1-11
Von Willebrand disease (VWD) and pregnancy: a comprehensive overview
Von Willebrand disease (VWD) is a hereditary bleeding disorder characterized by a quantitative or qualitative deficiency of von Willebrand factor (VWF). Pregnancy significantly impacts hemostasis, leading to a hypercoagulable state. However, women with VWD experience unique challenges due to the interplay between pregnancy-related hormonal changes and VWF deficiencies. This review delves into the intricate relationship between VWD and pregnancy. We explored the physiological changes that occur during pregnancy, including hormonal fluctuations, hemodilution, and alterations in platelet–VWF interactions. We discuss how these changes can exacerbate bleeding tendencies in women with VWD, particularly during childbirth and the postpartum period. This review highlights the increased risk of postpartum hemorrhage (PPH) in women with VWD and the potential for severe maternal morbidity and mortality. We examine the various types of VWD and their specific implications for pregnancy outcomes. Additionally, we discuss the challenges associated with diagnosing and managing VWD during pregnancy, as well as the importance of prenatal counseling and careful monitoring. The management of VWD during pregnancy involves a multidisciplinary approach, including the use of prophylactic treatments, such as desmopressin and tranexamic acid, as well as factor replacement therapy when necessary. Careful planning of delivery, including the choice of delivery mode and the timing of interventions, is essential to minimize bleeding complications. By understanding the complexities of VWD during pregnancy and implementing appropriate management strategies, healthcare providers can significantly improve the outcomes for women with VWD and their offspring.
- 28 April 2025
- Published by Springer Nature in Thrombosis Journal
- Vol. 23 (1) , 1-11
Open AccessVon Willebrand disease (VWD) and pregnancy: a comprehensive overview
Von Willebrand disease (VWD) is a hereditary bleeding disorder characterized by a quantitative or qualitative deficiency of von Willebrand factor (VWF). Pregnancy significantly impacts hemostasis, leading to a hypercoagulable state. However, women with VWD experience unique challenges due to the interplay between pregnancy-related hormonal changes and VWF deficiencies. This review delves into the intricate relationship between VWD and pregnancy. We explored the physiological changes that occur during pregnancy, including hormonal fluctuations, hemodilution, and alterations in platelet–VWF interactions. We discuss how these changes can exacerbate bleeding tendencies in women with VWD, particularly during childbirth and the postpartum period. This review highlights the increased risk of postpartum hemorrhage (PPH) in women with VWD and the potential for severe maternal morbidity and mortality. We examine the various types of VWD and their specific implications for pregnancy outcomes. Additionally, we discuss the challenges associated with diagnosing and managing VWD during pregnancy, as well as the importance of prenatal counseling and careful monitoring. The management of VWD during pregnancy involves a multidisciplinary approach, including the use of prophylactic treatments, such as desmopressin and tranexamic acid, as well as factor replacement therapy when necessary. Careful planning of delivery, including the choice of delivery mode and the timing of interventions, is essential to minimize bleeding complications. By understanding the complexities of VWD during pregnancy and implementing appropriate management strategies, healthcare providers can significantly improve the outcomes for women with VWD and their offspring.